A prospective trial evaluated the efficacy and pharmacokinetics of ledipasvir/sofosbuvir and ribavirin in patients with decompensated cirrhosis
Latest Information Update: 13 Nov 2017
Price :
$35 *
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Expanded access; Pharmacokinetics
- 24 Oct 2017 Results presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases
- 12 Mar 2016 New trial record